Last reviewed · How we verify
NCT06940401
JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations
Phase 1, PHASE2 trial testing JS111 capsules (AP-L1898) in NSCLC in 42 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Suzhou Junjing BioSciences Co., Ltd. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 42 |
| Start date | 30 April 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 5 November 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- JS111 capsules (AP-L1898) — full drug profile →
Conditions studied
- NSCLC — all drugs for NSCLC →
Sponsor
Suzhou Junjing BioSciences Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with NSCLC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the safety, tolerability, and preliminary efficacy of JS111 capsules in patients with locally advanced, metastatic, or recurrent NSCLC harboring EGFR mutations;to determine the recommended Phase II dose (RP2D).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06940401
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for NSCLC
Currently open trials in the same condition.
- NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
- NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
- NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting
Other Suzhou Junjing BioSciences Co., Ltd. trials
Trials by the same sponsor.
- NCT06909136 — A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With · Phase 1, PHASE2 · active not recruiting
- NCT05662670 — A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · terminated
- NCT05470933 — A Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors · Phase 1 · terminated
- NCT05326035 — A Study of WJ05129 in Advanced Malignant Solid Tumors · Phase 1, PHASE2 · terminated
- NCT04991129 — The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06940401 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Suzhou Junjing BioSciences Co., Ltd.
- Last refreshed: 14 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06940401.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing